Avidity Biosciences (RNA) Competitors $48.47 +0.88 (+1.85%) Closing price 04:00 PM EasternExtended Trading$48.38 -0.09 (-0.20%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. TEVA, SMMT, GMAB, VTRS, RDY, ASND, QGEN, MRNA, BBIO, and ELANShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Elanco Animal Health Teva Pharmaceutical Industries (NYSE:TEVA) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts recommend TEVA or RNA? Teva Pharmaceutical Industries currently has a consensus price target of $24.71, indicating a potential upside of 33.41%. Avidity Biosciences has a consensus price target of $67.00, indicating a potential upside of 38.23%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06 Do insiders and institutionals have more ownership in TEVA or RNA? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is TEVA or RNA more profitable? Teva Pharmaceutical Industries has a net margin of -0.95% compared to Avidity Biosciences' net margin of -4,247.77%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Avidity Biosciences -4,247.77%-33.45%-30.22% Which has more risk & volatility, TEVA or RNA? Teva Pharmaceutical Industries has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Which has better valuation and earnings, TEVA or RNA? Avidity Biosciences has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.28-$1.64B-$0.16-115.78Avidity Biosciences$10.90M572.08-$322.30M-$3.56-13.62 Does the media prefer TEVA or RNA? In the previous week, Teva Pharmaceutical Industries had 4 more articles in the media than Avidity Biosciences. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 10 mentions for Avidity Biosciences. Teva Pharmaceutical Industries' average media sentiment score of 1.14 beat Avidity Biosciences' score of 1.09 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTeva Pharmaceutical Industries beats Avidity Biosciences on 10 of the 17 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.24B$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-13.6221.0283.0126.65Price / Sales572.08379.56503.05163.66Price / CashN/A43.5325.7028.92Price / Book5.238.1210.796.52Net Income-$322.30M-$53.35M$3.29B$266.21M7 Day Performance-0.23%0.05%0.01%-0.76%1 Month Performance29.81%7.08%7.06%3.83%1 Year Performance16.21%11.92%50.09%24.39% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences3.2021 of 5 stars$48.47+1.8%$67.00+38.2%+16.1%$6.12B$10.90M-13.62190Positive NewsTEVATeva Pharmaceutical Industries3.3971 of 5 stars$18.14-1.7%$24.71+36.2%+1.3%$21.17B$16.54B-113.3836,830News CoveragePositive NewsSMMTSummit Therapeutics3.3459 of 5 stars$26.27+0.3%$32.85+25.0%+86.7%$19.46B$700K-26.01110News CoverageAnalyst ForecastOptions VolumeGMABGenmab A/S4.0508 of 5 stars$24.31-1.4%$37.60+54.7%-1.2%$15.81B$3.12B12.222,682VTRSViatris1.796 of 5 stars$10.55-0.9%$10.40-1.4%-11.3%$12.42B$14.74B-3.6432,000RDYDr. Reddy's Laboratories2.7962 of 5 stars$14.46-0.4%$16.95+17.3%-12.6%$12.11B$3.81B21.9027,811Positive NewsASNDAscendis Pharma A/S3.4536 of 5 stars$190.37-2.0%$243.36+27.8%+48.5%$11.89B$393.54M-36.891,017News CoveragePositive NewsAnalyst ForecastQGENQIAGEN4.2785 of 5 stars$48.92-1.6%$49.69+1.6%+8.4%$11.06B$1.98B28.905,765Positive NewsMRNAModerna4.4241 of 5 stars$25.35-6.5%$42.88+69.2%-67.0%$10.55B$3.24B-3.375,800BBIOBridgeBio Pharma4.1821 of 5 stars$47.29-3.6%$61.35+29.7%+80.4%$9.38B$221.90M-11.56400News CoveragePositive NewsAnalyst ForecastELANElanco Animal Health3.1154 of 5 stars$17.80-0.6%$17.33-2.6%+14.4%$8.90B$4.48B20.709,000Analyst Revision Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors QIAGEN Competitors Moderna Competitors BridgeBio Pharma Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
